Boston Scientific stock faces negative outlook as growth slows
Published on 11/09/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth pressure meets credit concerns
- S&P Global Ratings revised Boston Scientific's outlook to negative while affirming its A- issuer rating.
- The agency expects revenue growth of 4.4 percent in 2026 and 9 percent in 2027.
- The planned Penumbra acquisition could lift adjusted leverage above 3.6 times after closing.
Boston Scientific stock traded at 39.11 euros on Lang & Schwarz at 16:05 CET on Monday, November 9, 2026, 1.22 percent above the 38.64-euro quote in the company's earlier report at 12:51 CET. The move since that report is separate from any Xetra daily comparison.
S&P flags weaker growth
S&P Global Ratings revised Boston Scientific's outlook to negative from stable on Friday, November 6, while affirming the medical-device maker's A- issuer and senior unsecured debt ratings. The agency cited pressure on the WATCHMAN and electrophysiology franchises.
In its research update, S&P Global Ratings projects revenue growth of 4.4 percent for 2026 and 9 percent for 2027. That is below the mid- to high-teens growth rates achieved in 2024 and 2025, according to the agency.
Penumbra raises execution demands
The planned 14.5 billion US dollar acquisition of Penumbra is expected to close in early 2027. S&P Global Ratings expects adjusted leverage to rise above 3.6 times after completion, well above its 2.5-times downside trigger, and to remain elevated for an extended period.
The agency also expects Boston Scientific to pursue 500 million US dollars in restructuring savings through 2029. Its assessment depends on stabilizing WATCHMAN, restoring growth in electrophysiology, integrating Penumbra and maintaining a conservative financial policy.
What investors should watch
For investors, the central issue is whether the company's broader portfolio can offset pressure in its two important growth franchises while management integrates Penumbra. S&P Global Ratings expects Boston Scientific to work back toward leverage of 2.5 times by the end of 2028, but that outlook depends on execution across several fronts.
Boston Scientific Corporation
- ISIN: US1011371077
- Ticker: BSX
- Lang & Schwarz quote: 39.11 euros, Monday, November 9, 2026, 16:05 CET
- Change since earlier report: 1.22 percent from 38.64 euros at 12:51 CET
Investors can follow the broader US market through the S&P 500 market theme.
More news and analyses on Boston Scientific stock.
